4SC AG announced that composition of matter patents for a group of molecules including 4SC-208, an orally-available hedgehog/GLI signaling inhibitor in formal preclinical testing for the treatment of Hedgehog-driven cancers, were granted in further geographic regions. The patents now not only provide 4SC with market exclusivity until 2033 in the U.S. but also in China, Japan, Singapore, Australia and New Zealand.